Cambridge Cancer Genomics Overview

  • Founded
  • 2017
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 7
Employees
  • Latest Deal Type
  • M&A

Cambridge Cancer Genomics General Information

Description

Developer of a medical test platform designed to track the response to cancer therapy. The company's platform monitors the proportion of circulating tumor DNA in a patient's blood sample to determine how a patient is responding to therapy, enabling clinicians to monitor treatment response in near real-time, leading to rapid decision-making on the choice of therapy to improve patient quality of life and survival rates.

Contact Information

Website
www.ccg.ai
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Decision/Risk Analysis
Other Industries
Other Healthcare Technology Systems
Parent Company
Primary Office
  • 72 Hills Road
  • Cambridge CB2 1LA
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cambridge Cancer Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 23-Jun-2021 000.00 Completed Generating Revenue
9. Secondary Transaction - Private 000.00 Completed Generating Revenue
8. Early Stage VC 03-Jul-2020 00.00 000.00 0000 Completed Generating Revenue
7. Accelerator/Incubator 30-Jan-2020 00.000 Completed Generating Revenue
6. Early Stage VC 18-Dec-2018 00.00 00.000 Completed Generating Revenue
5. Early Stage VC 01-Nov-2017 00.000 00.000 Completed Startup
4. Early Stage VC 22-Aug-2017 00.00 00.000 Completed Startup
3. Accelerator/Incubator 21-Aug-2017 00000 00000 00.000 Completed Startup
2. Early Stage VC 01-Aug-2017 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Cambridge Cancer Genomics’s complete valuation and funding history, request access »

Cambridge Cancer Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Cambridge Cancer Genomics’s complete cap table history, request access »

Cambridge Cancer Genomics Executive Team (6)

Name Title Board Seat Contact Info
John Cassidy Ph.D Co-Founder & Chief Executive Officer
Harry Clifford Co-Founder & Chief Technology Officer
Nirmesh Patel Ph.D Co-Founder & Chief Scientific Officer
Emil Hewage Ph.D Founding Advisor
You’re viewing 4 of 6 executive team members. Get the full list »

Cambridge Cancer Genomics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cambridge Cancer Genomics Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AME Cloud Ventures Venture Capital Minority 000 0000 000000 0
Amplify Partners Venture Capital Minority 000 0000 000000 0
Comprehensive Blood & Cancer Center Other Minority 000 0000 000000 0
Endure Capital Venture Capital Minority 000 0000 000000 0
Flight Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »